LUND, SWEDEN -- (MARKET WIRE) -- March 09, 2007 -- Active Biotech (ACTI.ST), today announced new positive clinical data from the Phase Ib study of TASQ, for the treatment of prostate cancer.
LUND, SWEDEN -- (MARKET WIRE) -- March 09, 2007 -- Active Biotech (ACTI.ST), today announced new positive clinical data from the Phase Ib study of TASQ, for the treatment of prostate cancer.